Tarsus Pharmaceuticals (TARS) EBITDA Margin Growth (1y) (2022 - 2026)
Tarsus Pharmaceuticals (TARS) EBITDA Margin Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1,552.00 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1,536.00 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -170.00 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1,049.00 |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Tarsus Pharmaceuticals | 2.52 Bn | 2.41 Bn | 152.66 Mn | 2,977.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,977.00 |
| Dec 31, 2025 | 3,152.00 |
| Sep 30, 2025 | 4,005.00 |
| Jun 30, 2025 | 5,999.00 |
| Mar 31, 2025 | 10,292.00 |
| Dec 31, 2024 | 30,316.00 |
| Sep 30, 2024 | 213,558.00 |
| Mar 31, 2024 | 86,161.00 |
| Dec 31, 2023 | -18,933.00 |
| Mar 31, 2023 | 262,363.00 |
| Dec 31, 2022 | 412,395.00 |
| Jun 30, 2022 | -6,727.00 |
| Mar 31, 2022 | -365,375.00 |